Resultats globals: 7 registres trobats en 0.02 segons.
Articles, 6 registres trobats
Documents de recerca, 1 registres trobats
Articles 6 registres trobats  
1.
18 p, 288.5 KB Translational research opportunities regarding homologous recombination in ovarian cancer / Romeo Marín, Margarita (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Pardo, J.C. (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Martínez Cardús, Anna (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Martínez Balibrea, Eva (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Quiroga, Vanesa (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Martínez Román, Sergio (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Solé, Francesc (Institut Germants Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Margelí, Mireia (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Mesía, Ricard (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Universitat Autònoma de Barcelona
Homologous recombination (HR) is a DNA repair pathway that is deficient in 50% of high-grade serous ovarian carcinomas (HGSOC). Deficient HR (DHR) constitutes a therapeutic opportunity for these patients, thanks to poly (ADP-ribose) polymerases (PARP) inhibitors (PARPi; olaparib, niraparib, and rucaparib are already commercialized). [...]
2018 - 10.3390/ijms19103249
International Journal of Molecular Sciences, Vol. 19 Núm. 10 (19 2018) , p. 3249  
2.
10 p, 1.9 MB Nuclear IGF-1R predicts chemotherapy and targeted therapy resistance in metastatic colorectal cancer / Codony Servat, Jordi (Institut Germans Trias i Pujol. Institut Català d'Oncologia) ; Cuatrecasas Freixas, Miriam ; Asensio, Elena (Institut D'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)) ; Montironi, Carla (Hospital Clínic) ; Martínez Cardús, Anna (Institut Germans Trias i Pujol. Institut Català d'Oncologia) ; Marín Aguilera, Mercedes (Institut D'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)) ; Horndler, Carlos (Hospital Miguel Servet) ; Martínez Balibrea, Eva (Institut Germans Trias i Pujol. Institut Català d'Oncologia) ; Rubini, Michele (Department of Experimental and Diagnostic Medicine, University of Ferrara) ; Jares, Pedro (Hospital Clínic) ; Reig, Oscar (Institut D'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)) ; Victoria, Iván (Medical Oncology Department, Hospital Clínic, Translational Genomics and Targeted Therapeutics in Solid Tumors Group, IDIBAPS, Universitat de Barcelona) ; Gaba, Lydia (Medical Oncology Department, Hospital Clínic, Translational Genomics and Targeted Therapeutics in Solid Tumors Group, IDIBAPS, Universitat de Barcelona) ; Martín Richard, Marta (Institut d'Investigació Biomèdica Sant Pau) ; Alonso, Vicente (Hospital Miguel Servet) ; Escudero, Pilar (Hospital Clínico Universitatio Lozano Blesa) ; Fernández-Martos, Carlos (Instituto Valenciano de Oncología) ; Feliu, Jaime (Hospital La Paz, CIBERONC) ; Méndez, Jose Carlos (Centro Oncológico de Galicia) ; Méndez, Miguel (Hospital de Móstoles) ; Gallego, Javier (Hospital de Elche) ; Salud, Antonieta (Hospital Arnau de Vilanova) ; Rojo, Federico (Pathology Department, Fundación Jiménez Diaz University) ; Castells, Antoni (Institut D'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)) ; Prat, Aleix (Institut D'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)) ; Rosell, Rafael (Institut Germans Trias i Pujol. Institut Català d'Oncologia) ; García-Albéniz, Xabier (Harvard T.H. Chan School of Public Health) ; Camps, Jordi (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, Fisiologia i Immunologia) ; Maurel, Joan (Institut D'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS))
Although chemotherapy is the cornerstone treatment for patients with metastatic colorectal cancer (mCRC), acquired chemoresistance is common and constitutes the main reason for treatment failure. Monoclonal antibodies against insulin-like growth factor-1 receptor (IGF-1R) have been tested in pre-treated mCRC patients, but results have been largely deceiving. [...]
2017 - 10.1038/bjc.2017.279
British Journal of Cancer, Vol. 117 (november 2017) , p. 1777-1786  
3.
4 p, 471.8 KB Epigenetic loss of the RNA decapping enzyme NUDT16 mediates C-MYC activation in T-cell acute lymphoblastic leukemia / Anadón, C (Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet) ; van Tetering, G (Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet) ; Ferreira, H J (Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet) ; Moutinho, C (Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet) ; Martínez-Cardús, A (Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet) ; Villanueva, A (Translational Research Laboratory, Catalan Institute of Oncology, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet) ; Soler, M (Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet) ; Heyn, H (Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet) ; Moran, S (Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet) ; Castro de Moura, M (Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet) ; Setien, F (Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet) ; Vidal, A (Department of Pathological Anatomy, Bellvitge University Hospital, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet) ; Genescà, E (Institut Germans Trias i Pujol) ; Ribera, J M (Institut Germans Trias i Pujol) ; Nomdedéu Guinot, Josep Francesc (Institut d'Investigació Biomèdica Sant Pau) ; Guil, S (Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet) ; Esteller, M (Institucio Catalana de Recerca i Estudis Avançats (ICREA)) ; Universitat Autònoma de Barcelona
2017 - 10.1038/leu.2017.99
Leukemia, Vol. 31 (04 2017) , p. 1622-1625  
4.
14 p, 4.9 MB Epigenetic inactivation of the putative DNA/RNA helicase SLFN11 in human cancer confers resistance to platinum drugs / Nogales, Vanesa (Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Catalonia, Spain) ; Reinhold, William C. (Genomics and Bioinformatics Group, Developmental Therapeutics Branch, National Cancer Institute, Bethesda, MD, USA) ; Varma, Sudhir (Developmental Therapeutics Branch and Laboratory of Molecular Pharmacology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA) ; Martinez-Cardus, Anna (Institut de Recerca Biomèdica Bellvitge (IDIBELL)) ; Moutinho, Catia (Institut de Recerca Biomèdica Bellvitge (IDIBELL)) ; Moran, Sebastian (Institut de Recerca Biomèdica Bellvitge (IDIBELL)) ; Heyn, Holger (Institut de Recerca Biomèdica Bellvitge (IDIBELL)) ; Sebio, Ana (Institut d'Investigació Biomèdica Sant Pau) ; Barnadas i Molins, Agustí (Institut d'Investigació Biomèdica Sant Pau) ; Pommier, Yves (Developmental Therapeutics Branch and Laboratory of Molecular Pharmacology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA) ; Esteller, Manel (Institucio Catalana de Recerca i Estudis Avançats (ICREA)) ; Universitat Autònoma de Barcelona
Platinum-derived drugs such as cisplatin and carboplatin are among the most commonly used cancer chemotherapy drugs, but very few specific molecular and cellular markers predicting differential sensitivity to these agents in a given tumor type have been clearly identified. [...]
2015 - 10.18632/oncotarget.6413
Oncotarget, Vol. 7 (november 2015) , p. 3084-3097  
5.
17 p, 2.9 MB Curcumin mediates oxaliplatin-acquired resistance reversion in colorectal cancer cell lines through modulation of CXC-Chemokine/NF-κB signalling pathway / Ruiz de Porras, Vicenç (Institut Germans Trias i Pujol) ; Bystrup, Sara (Institut Germans Trias i Pujol) ; Martínez Cardús, Anna (Institut d'Investigació Biomèdica de Bellvitge) ; Pluvinet, Raquel (Institut Germans Trias i Pujol. Institut de Medicina Predictiva i Personalitzada del Càncer) ; Sumoy, Lauro (Institut Germans Trias i Pujol. Institut de Medicina Predictiva i Personalitzada del Càncer) ; Howells, Lynne (University of Leicester. Departament of Cancer Studies) ; James, Mark I. (University of Leicester. Departament of Cancer Studies) ; Iwuji, Chinenye (University of Leicester. Departament of Cancer Studies) ; Manzano, José Luis (Institut Germans Trias i Pujol) ; Layos, Laura (Institut Germans Trias i Pujol) ; Bugés, Cristina (Institut Germans Trias i Pujol) ; Abad, Albert (Hospital Cima Sanitas (Barcelona)) ; Martínez Balibrea, Eva (Institut Germans Trias i Pujol)
Resistance to oxaliplatin (OXA) is a complex process affecting the outcomes of metastatic colorectal cancer (CRC) patients treated with this drug. De-regulation of the NF-κB signalling pathway has been proposed as an important mechanism involved in this phenomenon. [...]
2016 - 10.1038/srep24675
Scientific reports, Vol. 6 (April 2016)  
6.
20 p, 10.3 MB PKM2 subcellular localization is involved in oxaliplatin resistance acquisition in HT29 human colorectal cancer cell lines / Ginés Molina, Alba (Institut Germans Trias i Pujol) ; Bystrup, Sara (Institut Germans Trias i Pujol) ; Ruiz de Porras, Vicenç (Institut Germans Trias i Pujol) ; Guardia, Cristina (Institut Germans Trias i Pujol) ; Musulén Palet, Eva (Institut Germans Trias i Pujol) ; Martínez Cardús, Anna (Institut Germans Trias i Pujol) ; Manzano, José Luis (Institut Germans Trias i Pujol) ; Layos, Laura (Institut Germans Trias i Pujol) ; Abad, Albert (Institut Germans Trias i Pujol) ; Martínez Balibrea, Eva (Institut Germans Trias i Pujol)
Chemoresistance is the main cause of treatment failure in advanced colorectal cancer (CRC). However, molecular mechanisms underlying this phenomenon remain to be elucidated. In a previous work we identified low levels of PKM2 as a putative oxaliplatin-resistance marker in HT29 CRC cell lines and also in patients. [...]
2015 - 10.1371/journal.pone.0123830
PLoS One, Vol. 10, No. 5 (May 2015) , p. e0123830  

Documents de recerca 1 registres trobats  
1.
155 p, 2.6 MB Estudi farmacogenòmic per a la identificació de gens implicats en la resposta i l'adquisició de resistència a oxaliplatí en el càncer colorrectal / Martínez Cardús, Anna ; Abad, Albert, dir. (Institut Català d'Oncologia) ; Martínez Balibrea, Eva, dir. (Institut Català d'Oncologia) ; Rosell Costa, Rafael, dir. (Universitat Autònoma de Barcelona. Departament de Medicina)
L'oxaliplatí constitueix en l'actualitat un agent d'elecció en el tractament de quimioteràpia de malalts amb càncer colorrectal (CCR) avançat. Tot i els grans avenços en l'oncologia clínica i la genètica molecular, un dels principals obstacles de l'èxit del tractament del malalt oncològic segueix centrat en la resistència als tractaments de quimioteràpia. [...]
Nowadays, oxaliplatin is a chemotherapeutic agent widely used in the treatment of colorectal cancer (CRC). In spite of the large advances in clinical oncology and molecular genetics, one of the major obstacles to the ultimate success of cancer chemotherapy continues centered in the resistance to citotoxic compounds. [...]

Bellaterra : Universitat Autònoma de Barcelona, 2009  

Vegeu també: autors amb noms similars
1 Martinez-Cardus, Anna
1 Martínez-Cardús, Anna
1 Martínez-Cardús, Anna
Us interessa rebre alertes sobre nous resultats d'aquesta cerca?
Definiu una alerta personal via correu electrònic o subscribiu-vos al canal RSS.